Ibrutinib and Lenalidomide With Dose-Adjusted EPOCH-R in Patients With Relapsed/Refractory DLBCL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia and Lymphoma
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 1b/2 Study of Ibrutinib and Lenalidomide With Dose-Adjusted EPOCH-R in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Leukemia and Lymphoma 2021 Apr 15;[EPub Ahead of Print], WH Wilson, T Phillips, L Popplewell, S de Vos, S Chhabra, AS Kimball, D Beaupre, DW Huang, G Wright, K Kwei, J Ping, JK Neuenburg, LM StaudtFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.